Flow cytometry is a workhorse technique in research and development as well as in clinical laboratories for diagnosis and monitoring of disease. Standard flow cytometers use fluorescent tags, often conjugated to monoclonal antibodies, to give qualitative and quantitative information about specific molecules in the cell on a cell-by-cell basis at very high throughput. Metabolic imaging of cancer cells relying on measurements of the inherent fluorescence of the ubiquitous metabolic co-enzyme NADH (the reduced form of nicotinamide adenine dinucleotide), particularly the fluorescence lifetime of NADH, yields a robust, generalized indicator of carcinogenesis. This is based on the well-established ?Warburg Effect?, a shift from oxidative phosphorylation to glycolysis as the preferred metabolic pathway in many cancer cells, and the involvement of NADH as a key player in both of these pathways. However, most of this work has been done in the field of fluorescence lifetime imaging microscopy (FLIM), a low-throughput method not amenable to development of a clinical diagnostic assay. Translating this method to high-throughput flow cytometry would pave the way for such a clinical diagnostic test. Since the 1990?s, efforts to implement lifetime measurements in flow have been hampered by a variety of technical barriers associated with hardware cost and speed, and computationally intense analysis. This work overcomes these obstacles, leveraging an existing fluorescence lifetime flow cytometry platform and modifying it to create a built-for-purpose tool for cancer cell analysis using NADH fluorescence lifetime that also employs an innovative method for rapid data analysis which would enable on-line analysis and cell sorting. Feasibility will be demonstrated by challenging the system with a comprehensive set of verification and validation tests. The method requires no exogenous cell labeling, relying instead on the inherent fluorescence of NADH. This instrument will provide a unique, high-throughput, label-free method for cancer cell discrimination at the single- cell level compatible for use on both blood-borne cancer cells and dissociated cells from solid tumors. Such an instrument would speed cancer drug development; have utility in cancer diagnostics and monitoring cancer treatment; help identify and understand tumor heterogeneity and treatment-resistant subpopulations of cells; and could enable development of personalized treatment regimens.
Project Terms: Achievement; Acquired Immunodeficiency Syndrome; Algorithms; anticancer research; Antineoplastic Agents; base; Binding Proteins; Biological; Biological Assay; Blood; cancer cell; Cancer Diagnostics; cancer therapy; carcinogenesis; Cell Separation; Cells; Clinical; clinical diagnostics; Complex; Complex Mixtures; cost; Cultured Cells; Data Analyses; Deoxyglucose; Detection; Development; Diagnostic; diagnostic assay; Diagnostic tests; Discrimination; Disease; drug development; drug discovery; Electronics; Enzymes; Evaluation; Flow Cytometry; Fluorescence; fluorescence lifetime imaging; genomic profiles; Glycolysis; Individual; inhibitor/antagonist; innovation; instrument; Label; Laboratory Diagnosis; Lasers; Lead; Legal patent; Malignant Neoplasms; Measurement; Measures; Metabolic; Metabolic Diseases; metabolic imaging; Metabolic Pathway; metabolic profile; metabolomics; Methods; Mitochondria; mitochondrial dysfunction; Monitor; Monoclonal Antibodies; NADH; neoplastic cell; Nicotinamide adenine dinucleotide; novel; Optics; Oxidative Phosphorylation; Pathway interactions; Performance; personalized medicine; Physiologic pulse; Population; Potassium Cyanide; Preparation; Protocols documentation; rapid technique; Recurrence; Relapse; Reproducibility; Research; research and development; Resistance; Resolution; Respiration; Sampling; Solid Neoplasm; Speed; System; Techniques; Technology; Testing; therapy resistant; tool; transcriptome sequencing; Translating; Treatment Protocols; treatment response; tumor heterogeneity; verification and validation; Warburg Effect; Work;
